BJ-TSA-9 Activators
Family with sequence similarity 83, member A (FAM83A) is a protein encoded by the FAM83A gene in humans. It is part of the FAM83 protein family, characterized by a conserved domain of unknown function (DUF1669) at the N-terminus. The FAM83 family members, including FAM83A, are known to be involved in important cellular processes, though the precise mechanisms by which they function are not yet fully elucidated.
FAM83A is notably expressed in epithelial cells and has been implicated in the regulation of cell signaling pathways that are critical for cell proliferation, differentiation, and survival. It has gained attention due to its overexpression in various types of cancers, including breast, lung, and ovarian cancer, suggesting a potential role in tumorigenesis. In cancer cells, FAM83A may contribute to oncogenic signaling by interacting with and affecting components of key pathways such as the PI3K/AKT/mTOR and RAS/MAPK pathways, which are known for their involvement in promoting cell growth and preventing apoptosis.Further studies have indicated that FAM83A may serve as a biomarker for cancer prognosis and could be a target for intervention.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, an EGFR inhibitor, could indirectly impact FAM83A activity by modulating EGFR signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, another EGFR inhibitor, might also influence FAM83A through its effects on EGFR pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, could affect FAM83A activity indirectly by modulating the MAPK/ERK pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, might impact FAM83A through its broad effects on cell signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitors could indirectly influence FAM83A activity by affecting the PI3K/Akt signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitors might impact FAM83A through their effects on cell growth and survival pathways. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
AKT inhibitors could influence FAM83A activity indirectly by modulating the AKT signaling pathway. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
STAT3 inhibitors might affect FAM83A indirectly by impacting JAK/STAT signaling pathways. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
B-Raf inhibitors could indirectly impact FAM83A activity by affecting the MAPK/ERK signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MAPK inhibitors might influence FAM83A activity indirectly through their effects on the MAPK pathway. | ||||||